Journal: Biomedical Journal

Article Title: Anti-PD-L1 improves barrier function and reduces CD103 + DC cell accumulation by regulating gut and lung microbiota and its metabolites to alleviate asthma in juvenile mice

doi: 10.1016/j.bj.2025.100944

Figure Lengend Snippet: The effects of PD-L1 blockade on airway hyperresponsiveness, inflammatory cell infiltration, and the expression of immunoglobulin in lung tissues of asthmatic mice were investigated. (A) Hyperresponsive changes in the airways of mice detected after stimulation with different concentrations of acetylcholine. (B) Total cells in BALF. (C) Number of eosinophils in BALF. (D–E) The expression levels of OVA-IgE and IgG1 were measured in BALF. PD-L1, Programmed cell death ligand 1. OVA-IgE, Ovalbumin-specific Immunoglobulin E. OVA-IgG1, Ovalbumin-specific Immunoglobulin G1. Data were presented as mean ± SEM, * p < 0.05, ** p < 0.01, *** p < 0.001.

Article Snippet: Based on previous [ , , ] studies with appropriate modifications and our previous pre-experimental protocol, the anti-mouse PD-L1 monoclonal antibody (10 μg/g/mouse, BioXcell, 804722F1B, America) and rat IgG2b (Clone: LTF-2) isotype control antibody (10 μg/g/mouse, BioXcell, 767921D1, America) were administered by i.p. injection on days 0, 7, and 14 of sensitization and 21, 28, and 35 of challenge.

Techniques: Expressing